These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21182343)

  • 1. Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden.
    Ghatnekar O; Hjortsberg C; Gisslén M; Lindbäck S; Löthgren M
    Pharmacoeconomics; 2010; 28 Suppl 1():49-57. PubMed ID: 21182343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002.
    Fleishman JA; Gebo KA; Reilly ED; Conviser R; Christopher Mathews W; Todd Korthuis P; Hellinger J; Rutstein R; Keiser P; Rubin H; Moore RD;
    Med Care; 2005 Sep; 43(9 Suppl):III40-52. PubMed ID: 16116308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting.
    Torti C; Casari S; Palvarini L; Quiros-Roldan E; Moretti F; Leone L; Patroni A; Castelli F; Ripamonti D; Tramarin A; Carosi G
    Health Policy; 2003 Sep; 65(3):261-7. PubMed ID: 12941493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost of managing HIV infection in highly treatment-experienced, HIV-infected adults in France.
    Colin X; Lafuma A; Costagliola D; Lang JM; Guillon P
    Pharmacoeconomics; 2010; 28 Suppl 1():59-68. PubMed ID: 21182344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.
    Krentz HB; Auld MC; Gill MJ;
    CMAJ; 2003 Jul; 169(2):106-10. PubMed ID: 12874156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs.
    Keiser P; Nassar N; Kvanli MB; Turner D; Smith JW; Skiest D
    J Acquir Immune Defic Syndr; 2001 May; 27(1):14-9. PubMed ID: 11404515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of highly active antiretroviral therapy in South Africa.
    Badri M; Maartens G; Mandalia S; Bekker LG; Penrod JR; Platt RW; Wood R; Beck EJ
    PLoS Med; 2006 Jan; 3(1):e4. PubMed ID: 16318413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
    Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
    AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated direct costs of medical care for HIV-infected patients within a regional population from 2006 to 2017.
    Krentz HB; Vu Q; Gill MJ
    HIV Med; 2020 May; 21(5):289-298. PubMed ID: 31852032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the cost to rural ambulating HIV/AIDS patients on highly active antiretroviral therapy (HAART) in rural Ghana: a pilot study.
    Apanga S; Punguyire D; Adjei G
    Pan Afr Med J; 2012; 12():21. PubMed ID: 22826745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use and cost of hospital and community service provision for children with HIV infection at an English HIV referral centre.
    Beck EJ; Mandalia S; Griffith R; Beecham J; Walters MD; Boulton M; Miller DL
    Pharmacoeconomics; 2000 Jan; 17(1):53-69. PubMed ID: 10747765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy.
    Garattini L; Tediosi F; Di Cintio E; Yin D; Parazzini F;
    AIDS Care; 2001 Dec; 13(6):733-41. PubMed ID: 11720643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drugs for antiretroviral therapy. The costs of HAART].
    Jablonowski H
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():21. PubMed ID: 19024911
    [No Abstract]   [Full Text] [Related]  

  • 14. The economic burden of late entry into medical care for patients with HIV infection.
    Fleishman JA; Yehia BR; Moore RD; Gebo KA;
    Med Care; 2010 Dec; 48(12):1071-9. PubMed ID: 21063228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric HIV costs across three treatment eras from 1986 to 2007.
    Wilson LS; Basu R; Christenson M; Hensic L; Paoli C; Wara D; Moskowitz JT
    Pediatrics; 2010 Sep; 126(3):e541-9. PubMed ID: 20696721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.
    Hill AM; Gebo K; Hemmett L; Löthgren M; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():169-81. PubMed ID: 21182350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the use of health resources by Spanish and immigrant HIV-infected patients.
    Velasco M; Castilla V; Guijarro C; Moreno L; Barba R; Losa JE
    Enferm Infecc Microbiol Clin; 2012 Oct; 30(8):458-62. PubMed ID: 22377495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US.
    Lacey L; Mauskopf J; Lindrooth R; Pham S; Saag M; Sawyer W
    Pharmacoeconomics; 1999; 15 Suppl 1():23-37. PubMed ID: 10537440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The costs of providing antiretroviral therapy services to HIV-infected individuals presenting with advanced HIV disease at public health centres in Dar es Salaam, Tanzania: Findings from a randomised trial evaluating different health care strategies.
    Kimaro GD; Mfinanga S; Simms V; Kivuyo S; Bottomley C; Hawkins N; Harrison TS; Jaffar S; Guinness L;
    PLoS One; 2017; 12(2):e0171917. PubMed ID: 28234969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of management strategies and clinical status on costs of care for advanced HIV.
    Barnett PG; Chow A; Joyce VR; Bayoumi AM; Griffin SC; Sun H; Holodniy M; Brown ST; Cameron W; Sculpher M; Youle M; Anis AH; Owens DK
    Am J Manag Care; 2014 May; 20(5):e129-37. PubMed ID: 25326927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.